New Delhi, Dec 30, 2014 – Drug major Lupin has received US health regulator’s approval to market a generic version of ViiV Healthcare’s Epivir Tablets, used in treating HIV infection, in the American market.
The Mumbai-based firm has received final approval from the US Food and Drug Administration ( USFDA) for itsLamivudine tablets in strengths of 150 mg and 300 mg, Lupin Ltd said in a statement.
Lupin Pharmaceuticals Inc (LPI), the company’s US subsidiary, would commence marketing the product shortly, it added.
Epivir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection.
According to IMS MAT September 2014 sales data, Epivir tablets had annual US sales of USD 39.7 million.
Lupin shares were trading at Rs 1,401 apiece on the BSE, down 0.12 per cent from their previous close. PTI
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…